ABSTRACT To investigate the mechanism by which nifedipine improves exercise tolerance in patients with coronary artery disease, we studied 14 patients with stable exertional angina and left anterior descending artery disease by measuring great cardiac vein flow (GCVF) and calculating anterior regional coronary resistance (ARCR) during exercise before and after sublingual administration of 20 mg of nifedipine. After nifedipine seven patients (group I) had no increase in exercise capacity and showed a similar magnitude of ST segment depression at peak exercise, while another seven patients (group II) had prolonged exercise duration (p < .001) with less ST segment depression at peak exercise (p < .01). Such effects were achieved despite a significant increase in double product, an indirect index of myocardial oxygen consumption. In group I patients no significant change was induced by nifedipine in GCVF or in ARCR either at rest or at peak exercise. In contrast, in group II patients nifedipine significantly increased GCVF at rest (p < .05) and at peak exercise (p < .001). Moreover, resting ARCR was decreased (p < .01) and remained significantly lower at peak exercise (p < .01) compared with the prenifedipine values. These data show that nifedipine may increase GCVF and decrease ARCR at rest and at peak exercise in patients with left anterior descending artery disease. Such increase in myocardial oxygen supply seems the most likely mechanism by which nifedipine may improve exercise capacity in patients with stable exertional angina.
Circulation 68, No. 5, [1035] [1036] [1037] [1038] [1039] [1040] [1041] [1042] [1043] 1983 . THE BENEFICIAL EFFECTS of nifedipine, a calcium-channel blocker, in the medical management of angina at rest have been well established, particularly in those patients in whom coronary spasm plays a major role in the pathogenesis of myocardial ischemia.'-3 Several studies have also shown that nifedipine provides substantial benefits to patients with classic exercise-induced angina pectoris. Such salutary action has been ascribed to the reduction in myocardial oxygen consumption that is a result of decreased systemic vascular resistance.9 However, some investigators have demonstrated that intracoronary infusion of nifedipine has the same antianginal efficacy as intravenous administration, despite the absence of significant peripheral hemodynamic effects. '0 Moreover, a druginduced increase in resting myocardial blood flow distal to significant coronary obstructions has been shown in patients with coronary artery disease, suggesting that a direct increase in myocardial oxygen supply could represent a potential alternative mechanism by which nifedipine may exert its antianginal effect.1 ' The present study was designed to determine whether the increase in coronary flow induced by nifedipine could be of benefit in patients with exertional angina. We examined a homogeneous population of patients with stable exercise-induced angina and left anterior descending artery disease. Great cardiac vein flow (GCVF), representing the venous efflux from the left ventricular region supplied by this artery,'2 was measured by the thermodilution technique'3 14 during a supine bicycle exercise test performed before and after sublingual administration of nifedipine. The effects of nifedipine on exercise tolerance were then related to the drug-induced changes in coronary vascular hemodynamics observed during exercise.
Vol. 68, No. 5, November 1983 Methods Study patients. The study group consisted of 14 patients ( 1 men and three women) selected from those referred for cardiac catheterization to further determine the cause of their chest pain.
All patients complained of stable exertional angina and had a positive exercise test result, defined as the development of chest pain and 3l1 mm ST segment depression. Patients who predominantly had angina at rest or showed ST segment elevation suggestive of variant angina were excluded from the study. No patient had clinical evidence of heart failure or had had a recent myocardial infarction (within 6 weeks of the study). In all patients selective coronary arteriography, performed by the Sones technique, revealed a significant narrowing (>50% reduction in luminal diameter, as measured from multiple projections) of the left anterior descending artery proximal to the first septal branch, which was associated in four patients with nonsignificant stenoses of other coronary vessels.
Procedure. All patients were studied in the fasting state 1 to 5 days after coronary arteriography and none received premedication. Nitrates and nifedipine were suspended 12 hr before the study; four patients who were taking 83-blockers were gradually weaned from them and the drug was discontinued at least I week before the study. None of the patients were taking verapamil or diltiazem. With patients in the supine position triplethermistor thermodilution catheters14 were inserted into the left arm antecubital veins and advanced under fluoroscopy into the coronary sinus with the tips positioned in the great cardiac vein. The position was confirmed by fluoroscopy and frequently checked throughout the procedure. Once the catheter was positioned, resting GCVF was determined by continuous infusion per 30 sec of a physiologic saline solution at 24 degrees with a pump at a rate of 56 ml/min. Arterial blood pressure was recorded continuously by means of a No. 20 Teflon cannula in a radial artery. A bicycle exercise test was then performed by each patient in the supine position at an initial workload of 25 W, with subsequent increments of 25 W every 3 min. When angina occurred GCVF was measured for 30 sec and then the exercise test was stopped. A 12-lead electrocardiogram (ECG) was recorded before and at the end of exercise, and leads V4, V5, and V6 were monitored during exercise. Thirty minutes after termination of the exercise test, 20 mg of nifedipine was administered sublingually. Twenty minutes later all baseline data were collected and the exercise test was repeated according to the prenifedipine protocol. GCVF was measured again during the last 30 sec of exercise, which was then stopped because of angina or exhaustion. The 14 patients were divided into two groups according to their responses to the exercise tests after nifedipine. Group I included seven patients in whom exercise capacity did not improve after the drug; they complained of chest pain either at the same time or earlier during the second exercise test. Group II included seven patients who had increased exercise capacity after nifedipine; they tolerated higher workloads during the second test and chest pain either occurred later or not at all. Informed consent was obtained from all patients before the study. No complications were observed during the procedure.
Calculations and statistical analysis. GCVF was calculated according to the formula:
where Vi is rate of injection of indicator (56 ml/min), Tb is blood temperature before injection, Ti is temperature of the injectate measured by a thermistor in the lumen of the catheter during injection, TGCV is temperature of the mixture of great cardiac vein blood and injectate, and 1.08 ml/min is the constant-rate saline solution infusion.
Mean arterial pressure was obtained by electronic filtration. Anterior regional coronary resistance (in mm Hg/ml/min) was calculated as the quotient of mean aortic pressure and GCVF. Heart rate was calculated from the ECG. An estimate of myocardial oxygen consumption was made from the double product, obtained by multiplying systolic arterial pressure and heart rate. from 2.12 + 1.0 to 1.25 + 0.6 mm Hg/ml/min (p < .01). After nifedipine was given, resting heart rate increased (p < .01) and mean arterial pressure decreased (p < .01). Resting GCVF increased slightly but not significantly. Similarly, nifedipine induced a small but nonsignificant decrease in anterior regional coronary resistance. At peak exercise the values for GCVF and anterior regional coronary resistance were not significantly different from the values achieved at the same time before nifedipine (figure 1). Double product at peak exercise was not significantly different from the value achieved before nifedipine. Table 4 shows coronary hemodynamic findings during exercise in group IL patients. Before nifedipine GCVF increased at peak exercise from 74 + 27 to 113 + 35 ml/min (p < .01), while anterior regional coronary resistance declined slightly, but not significantly, from 1.61 + 0.52 to 1.23 ± 0.48 mm Hg/ml/min. Prenifedipine values of GCVF and anterior regional coronary resistance were not significantly different in the two groups of patients.
After nifedipine resting heart rate increased (p < .05), as did resting GCVF (p < .05), while mean arterial pressure decreased (p < .05), as did anterior regional coronary resistance (p < .01). During exercise GCVF increased (p < .001), while anterior regional coronary resistance decreased slightly but not significantly. As a result, at peak exercise GCVF was higher (p < .001) and anterior regional coronary resisVol. 68, No. 5, November 1983 left anterior descending artery; Cfx tance lower (p < .01) than before nifedipine (figure 2). Results in a representative patient are shown in figure  3 . The double product at peak exercise was higher after nifedipine (p < .05).
Discussion
Thermodilution measurements of coronary blood flow have provided important information about the pathogenesis of myocardial ischemia in patients with coronary artery disease.'5-' Recently Fuchs et al.'8 measured GCVF, the venous efflux from the territory of the left anterior descending artery, during incremental atrial pacing in 10 patients with left anterior descending artery disease. These authors found a characteristic failure to increase GCVF concomitant with the development of angina, representing flow limitation in the territory supplied by the diseased left anterior descending artery. In our study we measured GCVF under control conditions and at peak exercise (when angina occurred) in 14 patients with stable exertional angina and a severe proximal narrowing of the left anterior descending artery, which was associated in four patients with nonsignificant stenoses of other coronary vessels. In all patients GCVF increased during exercise. However, the increase fell short of myocardial oxygen requirements because chest pain associated with significant ST segment abnormalities occurred in all patients. Because of the coronary flow limitation phenomenon, GCVF at the time of exercise- HR = heart rate (beats/min); MAP = mean arterial pressure (mm Hg); DP = double product (mm Hg x beats/min x 10-2); GCVF = great cardiac vein flow (ml/min); ARCR = anterior regional coronary resistance (mm Hg/ml/min); Con = control; Ex = peak exercise; nife = nifedipine. 1 . In group I patients, in whom exercise capacity did not improve after nifedipine (NIFE), GCVF increased at peak exercise before (P.EX. I) and after (P.EX II) nifedipine, while anterior regional coronary resistance (ARCR) decreased in both exercise tests. No significant differences were found among GCVF and anterior regional coronary resistance values at control and at peak exercise before and after the drug. the different responses in the two groups were secondary to different absorption of the drug.
Several studies indicate that nifedipine improves exercise capacity in patients with exertional angina."
Such beneficial effects have been accounted for by the peripheral effects of the drug,9 which decreases systemic vascular resistance, and thus the left ventricular afterload, while having little effect on preload."9 The double product at peak exercise, an indirect index of myocardial oxygen consumption, has been reported to be either decreased or unchanged after nifedipine,jsuggesting that the drug improves exercise capacity by reducing myocardial oxygen demand at a given load. However, some investigators have found significant improvement in exercise tolerance after nifedipine despite higher heart rate and blood pressure at peak exercise. 20 Moreover, a significant reduction in exercise- induced ST segment depression was observed after intracoronary administration of 0.1 mg of nifedipine, a dose that did not induce peripheral hemodynamic effects. '°In our study the peak-exercise double product was significantly higher after nifedipine in the seven patients in whom the drug improved exercise capacity, suggesting that the mechanism by which nifedipine exerted its salutary action was not secondary to a reduction in myocardial oxygen consumption. It might be argued, however, that changes in other determinants of myocardial oxygen consumption not included in the calculation of double product could be responsible for the beneficial effects of the drug. Experimental data in isolated cardiac muscle preparations have shown that nifedipine decreases contractility,2' one important factor in determining myocardial oxygen consumption. This negative inotropic effect, however, is Changes in heart rate, mean arterial pressure, double product, and coronary hemodynamics during exercise in patients-in whom exercise capacity was improved after nifedipine (group II) In this study we did not evaluate changes in left ventricular filling pressure after nifedipine. A druginduced.decrease in left ventricular filling pressure would lead to a reduction in intramyocardial tension, resulting in decreased myocardial oxygen consumption. However, Ludbrook et al. 22 recently observed a significant decline in left ventricular end-diastolic pressure after nifedipine only in patients in whom baseline values exceeded 20 mm Hg. Because in our study the two groups of patients had similar control left ventricular end-diastolic pressures, the fact that the effects of nifedipine on exercise capacity differed does not seem to be attributable to a different action of the drug on left ventricular end-diastolic pressure.
One potential mechanism by which nifedipine may improve exercise capacity in patients with stable exertional angina is by increasing myocardial oxygen supply. Malacoff et al.1I found that nifedipine improved 1040 myocardial blood flow in regions supplied by vessels that had significant coronary obstructions, while it had the opposite effect in normal regions. In addition, Engel and Lichtlen23 noted an increase in coronary flow in poststenotic areas after nifedipine and these persisted during atrial pacing, whereas blood flow in normal areas remained essentially unchanged. Furthermore, Zacca et al.8 observed a definite increase in thallium uptake after nifedipine in five of 11 patients in whom exercise thallium-201 perfusion scintigraphy was performed, suggesting that nifedipine may improve myocardial perfusion. Moreover, a nifedipine-induced increase in coronary flow resulting in improved anginal threshold during exercise has been recently demonstrated in two patients with vasospastic angina.24 In the present study, nifedipine induced a significant increase in GCVF at rest and at peak exercise only in group II patients. Because thermodilution measurements of GCVF permit determination of transmural flow across the territory supplied by the left anterior descending artery only, we were unable to study flow distribution within the left ventricular wall. Coronary arteriolar vasodi ators such as chromonar25 and dipyridamole26 have been shown to provoke a maldistribution of coronary blood flow with a decreased endocardial/epicardi- In group II patients, in whom exercise capacity improved after nifedipine (NIFE), GCVF increased at peak exercise before (P.EX. I) and after (P.EX. II) nifedipine, while anterior regional coronary resistance (ARCR) decreased in both exercise tests. However, after nifedipine control and peak-exercise GCVFs were significantly higher than before the drug. Conversely, anterior regional coronary resistance was significantly lower after nifedipine under control conditions and at peak exercise.
al flow ratio, resulting in subendocardial ischemia. This condition was not observed in our group II patients, however, because ST segment depression, the ECG hallmark of subendocardial ischemia, was less pronounced during the exercise test performed after nifedipine. In these patients the nifedipine-induced increase in GCVF was accompanied by a decrease in anterior regional coronary resistance, which was significantly lower at rest and at peak exercise compared with the prenifedipine values. 
